| James F Flaherty, MD | |
|
40 Hart St, Bldg. D, New Britain, CT 06052-1743 | |
| (860) 827-1981 | |
| (860) 827-1642 |
| Full Name | James F Flaherty |
|---|---|
| Gender | Male |
| Speciality | Surgical Oncology |
| Experience | 34 Years |
| Location | 40 Hart St, New Britain, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518071513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 032774 (Connecticut) | Secondary |
| 2086X0206X | Surgery - Surgical Oncology | 032774 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital & Medical Center | Hartford, CT | Hospital |
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Health Of New England Provider Network Organization Inc | 0941113567 | 621 |
News Archive
In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.
One of the leading causes of inherited blindness in humans, retinitis pigmentosa, is analogous to retinal dystrophies that lead to blindness in dogs. Because of their similarities, identifying gene mutations underlying several types of canine retinal dystrophies has suggested courses for research on RP in humans. These advances are significant for both humans and dogs.
QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.
Applied Biosystems, part of Life Technologies Corporation, today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems' industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use.
Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study.
› Verified 6 days ago
| Entity Name | Trinity Health Of New England Provider Network Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003882812 PECOS PAC ID: 0941113567 Enrollment ID: O20031110000651 |
News Archive
In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.
One of the leading causes of inherited blindness in humans, retinitis pigmentosa, is analogous to retinal dystrophies that lead to blindness in dogs. Because of their similarities, identifying gene mutations underlying several types of canine retinal dystrophies has suggested courses for research on RP in humans. These advances are significant for both humans and dogs.
QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.
Applied Biosystems, part of Life Technologies Corporation, today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems' industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use.
Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James F Flaherty, MD 100 Grand St, Medical Staff Office: Ondrea Chasse, New Britain, CT 06052-2016 Ph: (860) 224-5305 | James F Flaherty, MD 40 Hart St, Bldg. D, New Britain, CT 06052-1743 Ph: (860) 827-1981 |
News Archive
In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.
One of the leading causes of inherited blindness in humans, retinitis pigmentosa, is analogous to retinal dystrophies that lead to blindness in dogs. Because of their similarities, identifying gene mutations underlying several types of canine retinal dystrophies has suggested courses for research on RP in humans. These advances are significant for both humans and dogs.
QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.
Applied Biosystems, part of Life Technologies Corporation, today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems' industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use.
Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study.
› Verified 6 days ago
Dr. Noubar Movses Kevorkian, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5513 Fax: 860-224-5916 | |
Parth S Shah, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart St, Bldg C, New Britain, CT 06052 Phone: 860-229-8889 Fax: 860-229-8893 | |
Mr. Terrence K Donahue, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart Street, Bldg D, New Britain, CT 06052 Phone: 860-826-5288 Fax: 860-225-9519 | |
Elizabeth Roderick, MD Surgery Medicare: Medicare Enrolled Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-972-9093 | |
Dr. Robert Napoletano, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Lake St, Grove Hill Medical Center, New Britain, CT 06052 Phone: 860-826-4457 Fax: 860-229-6963 | |
Justin Van Backer, Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St Dept Of, New Britain, CT 06052 Phone: 860-696-4923 | |
Christine Marie Bartus, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart St, Building C, New Britain, CT 06052 Phone: 860-229-8889 Fax: 860-229-8893 |